Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a stand-alone therapy for depression that has not responded to other options.

J&J announcement The FDA approved the supplement on Tuesday. Previously, Spravato was approved as an add-on therapy for treatment-resistant depression in combination with an oral antidepressant. Expanded use indicates a promising future for ketamine and similar drugs as mental health interventions.

You were good first approved By the FDA in 2019, subsequent years of research suggest that ketamine therapy may provide unique and fast-acting antidepressant benefits. Although ketamine is perhaps more notoriously known as a recreational drug with dissociative effects, it has long been used clinically as an anesthetic. Before Spravato’s approval, intravenous ketamine became a growing, if off-label, option in difficult cases of depression. However, spravato contains a different form of ketamine that is used intravenously—a chemical sibling called esketamine.

In the years since approval, spravato and ketamine have continued to demonstrate their potential as depression treatments. Studies after its publication found, for example, that ketamine can to cross Other standard options for treatment-resistant depression, such as certain antipsychotics. The FDA granted extended approval of Spravato based on a post-marketing Phase 4 trial, which compared Spravato to placebo alone.

The double-blind, randomized and controlled trial involved people with treatment-resistant depression, who were assigned to three groups: two groups that received different doses of Spravato twice a week for four weeks, and a control group that received a placebo spray. People on Spravato experienced significant and sustained reductions in depressive symptoms compared to controls, the study found. Only 7.6% of patients taking placebo had a marked reduction in their symptoms, for example, compared to 22.5% of people taking Spravato. The drug also appeared to be as safe as previous trials had shown.

“Drug-resistant depression can be very complex, especially for patients who do not respond to or cannot tolerate oral antidepressants,” said Bill Martin, Global Therapeutic Area Head of Neuroscience, J&J’s Innovative Medicine Division. statement. “Spravato is now available as a standalone treatment, meaning patients can experience improvement in depression symptoms within 24 hours and up to 28 days – without the need for daily oral antidepressants.”

Like any drug, ketamine is not without its risks. When used for depression, common side effects may include drowsiness, disorientation, and respiratory depression (slow or shallow breathing). Because of these side effects and the potential risk of harmful dependence, the FDA has mandated a special treatment strategy for giving Spravato to patients, known as a Risk Evaluation and Mitigation Strategy, or REMS, program. People taking Spravato should only do so at a clinic or medical office certified to dispense it and under direct medical supervision.

Still, Spravato’s expansion into a standalone therapy means that more people with treatment-resistant depression will be able to access the drug. In the long run, a big reason why researchers are so excited about ketamine is the drug aim Different receptors in the brain are implicated in depression compared to other drugs. This only allows ketamine to potentially help people who haven’t responded to past treatments, which may someday mean its arrival. new medicine That works the same way. And if these drugs can be made safer, they could also become frontline treatments for depression in general.